a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., active and no longer recruiting.
Overview
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors is a phase 1/2 interventional study registered as NCT06166836 by InxMed (Shanghai) Co., Ltd., with 140 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: D1553 and IN10018（Ifebemtinib）.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Shares InventisBio, IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialIN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Shares IN10018 and the tag pipeline.
- TreatmentD-0502
Shares InventisBio and the tag pipeline.
- TrialIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Shares IN10018 and the tag pipeline.
- TrialStudy to Evaluate D-1553 in Subjects With Solid Tumors
Shares InventisBio and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.